BMS-790052 (Daclatasvir)

Catalog No. A10159

BMS-790052 (Daclatasvir)是一种高度选择性的HCV NS5A抑制剂，EC50为9-50 pM，用于治疗丙型肝炎病毒（HCV）感染。

Product Citations

TS Wahyuni, .et al. Enhancement of Anti-Hepatitis C Virus Activity by the Combination of Chalepin From Ruta Angustifolia and Current Antiviral Drugs, Southeast Asian J Trop Med public health, 2020, 51(1)
Miyayama Y, .et al. Comparative study on the replication of HCV1b genome between wild type and cell culture adaptive mutant in regard to sensitivities against anti-HCV drugs, Microbiol Immunol, 2019, Dec 19 PMID: 31854467
Sato K, .et al. Elevated serum uric acid level was a notable adverse event during combination therapy with sofosbuvir and ribavirin, Hepatol Res, 2018, Feb;48(3):E347-E353 PMID: 28834004

Technical details

Catalog Num	A10159
M. Wt	738.9
Formula	C40H50N8O6
Purity	>98%
Storage	at -20°C 3 years Powder
CAS No.	1214735-16-6, 1009119-64-5
Synonyms	Daclatasvir
SMILES	CC(C)[C@@H](C(=O)N1CCC[C@H]1C2=NC=C(N2)C3=CC=C(C=C3)C4=CC=C(C=C4)C5=CN=C(N5)[C@@H]6CCCN6C(=O)[C@H](C(C)C)NC(=O)OC)NC(=O)OC

Biological Activity

BMS-790052 (Daclatasvir)是一种高度选择性的HCV NS5A抑制剂，EC50为9-50 pM，用于治疗丙型肝炎病毒（HCV）感染。

Solubility *

In vitro	DMSO	129 mg/mL (174.59 mM)
	Water	Insoluble
	Ethanol	129 mg/mL (174.59 mM)
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Preparing Stock Solutions

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.1 mM	13.53 mL	67.67 mL	135.34 mL
0.5 mM	2.71 mL	13.53 mL	27.07 mL
1 mM	1.35 mL	6.77 mL	13.53 mL
5 mM	0.27 mL	1.35 mL	2.71 mL

*The above data is based on the productmolecular weight 738.9 . Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.